Replies to post #101508 on Biotech Values

[MotionMan]

Which companies are possible suitors then? Do you think the limited partners is going to drastically affect their profit share/royalty rate where it would convince MNTA to pay for the Phase 2b trials on their own? What kind of upfront payment and % split can they expect to receive from a M118 deal.
Thanks.

[jq1234]

• PFE/BMY: Apixaban
• JNJ/Bayer: Xarelto
• MRK: Betrixaban
• Daiichi Sankyo: Edoxaban
• Boehringer Ingelheim: Pradaxa
• SNY: Otamixaban, AVE5026

I don't see Takeda's TAK-442 on the list.